Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

10.3389/fonc.2014.00058

Saved in:

Bibliographic Details
Main Authors:	Ou, S.-H.I, Soo, R.A, Kubo, A, Kawaguchi, T, Ahn, M.-J
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Review
Published:	2020
Subjects:	anaplastic lymphoma kinase brain derived neurotrophic factor receptor cabozantinib CD74 antigen crizotinib lenvatinib platelet derived growth factor alpha receptor platelet derived growth factor receptor ponatinib protein Ret protein tyrosine kinase protein tyrosine kinase A protein tyrosine kinase inhibitor Raf protein regorafenib sorafenib sunitinib vandetanib vasculotropin receptor 1 vasculotropin receptor 3 breast cancer chronic myelomonocytic leukemia clinical trial (topic) colorectal carcinoma cost effectiveness analysis DNA transfection drug approval drug industry fluorescence in situ hybridization food and drug administration gene rearrangement human immunohistochemistry lung non small cell cancer molecular diagnostics off label drug use reverse transcription polymerase chain reaction review sequence analysis sequence homology thyroid cancer
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183179
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183179
record_format	dspace
spelling	sg-nus-scholar.10635-1831792023-09-20T21:49:27Z Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally? Ou, S.-H.I Soo, R.A Kubo, A Kawaguchi, T Ahn, M.-J CANCER SCIENCE INSTITUTE OF SINGAPORE anaplastic lymphoma kinase brain derived neurotrophic factor receptor cabozantinib CD74 antigen crizotinib lenvatinib platelet derived growth factor alpha receptor platelet derived growth factor receptor ponatinib protein Ret protein tyrosine kinase protein tyrosine kinase A protein tyrosine kinase inhibitor Raf protein regorafenib sorafenib sunitinib vandetanib vasculotropin receptor 1 vasculotropin receptor 3 breast cancer chronic myelomonocytic leukemia clinical trial (topic) colorectal carcinoma cost effectiveness analysis DNA transfection drug approval drug industry fluorescence in situ hybridization food and drug administration gene rearrangement human immunohistochemistry lung non small cell cancer molecular diagnostics off label drug use reverse transcription polymerase chain reaction review sequence analysis sequence homology thyroid cancer 10.3389/fonc.2014.00058 Frontiers in Oncology 43559 Article 58 2020-11-10T00:26:54Z 2020-11-10T00:26:54Z 2014 Review Ou, S.-H.I, Soo, R.A, Kubo, A, Kawaguchi, T, Ahn, M.-J (2014). Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?. Frontiers in Oncology 43559 : Article 58. ScholarBank@NUS Repository. https://doi.org/10.3389/fonc.2014.00058 2234943X https://scholarbank.nus.edu.sg/handle/10635/183179 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	anaplastic lymphoma kinase brain derived neurotrophic factor receptor cabozantinib CD74 antigen crizotinib lenvatinib platelet derived growth factor alpha receptor platelet derived growth factor receptor ponatinib protein Ret protein tyrosine kinase protein tyrosine kinase A protein tyrosine kinase inhibitor Raf protein regorafenib sorafenib sunitinib vandetanib vasculotropin receptor 1 vasculotropin receptor 3 breast cancer chronic myelomonocytic leukemia clinical trial (topic) colorectal carcinoma cost effectiveness analysis DNA transfection drug approval drug industry fluorescence in situ hybridization food and drug administration gene rearrangement human immunohistochemistry lung non small cell cancer molecular diagnostics off label drug use reverse transcription polymerase chain reaction review sequence analysis sequence homology thyroid cancer
spellingShingle	anaplastic lymphoma kinase brain derived neurotrophic factor receptor cabozantinib CD74 antigen crizotinib lenvatinib platelet derived growth factor alpha receptor platelet derived growth factor receptor ponatinib protein Ret protein tyrosine kinase protein tyrosine kinase A protein tyrosine kinase inhibitor Raf protein regorafenib sorafenib sunitinib vandetanib vasculotropin receptor 1 vasculotropin receptor 3 breast cancer chronic myelomonocytic leukemia clinical trial (topic) colorectal carcinoma cost effectiveness analysis DNA transfection drug approval drug industry fluorescence in situ hybridization food and drug administration gene rearrangement human immunohistochemistry lung non small cell cancer molecular diagnostics off label drug use reverse transcription polymerase chain reaction review sequence analysis sequence homology thyroid cancer Ou, S.-H.I Soo, R.A Kubo, A Kawaguchi, T Ahn, M.-J Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
description	10.3389/fonc.2014.00058
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Ou, S.-H.I Soo, R.A Kubo, A Kawaguchi, T Ahn, M.-J
format	Review
author	Ou, S.-H.I Soo, R.A Kubo, A Kawaguchi, T Ahn, M.-J
author_sort	Ou, S.-H.I
title	Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
title_short	Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
title_full	Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
title_fullStr	Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
title_full_unstemmed	Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?
title_sort	will the requirement by the us fda to simultaneously co-develop companion diagnostics (cdx) delay the approval of receptor tyrosine kinase inhibitors for rtk-rearranged (ros1-, ret-, axl-, pdgfr-α-, ntrk1-) non-small cell lung cancer globally?
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183179
_version_	1779152954662584320

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

Similar Items